To evaluate the safety and efficacy of Danlong Oral Liquid in the treatment of bronchial asthma(heat wheezing syndrome) under widespread use conditions.Methods:A total of 2 000 bronchial asthma patients with heat wheezing syndrome who met the inclusion criteria were enrolled and administered Danlong Oral Liquid(10 mL per dose,3 times daily) for 7 days in addition to their routine treatment.Changes in efficacy indicators,including traditional Chinese medicine(TCM) syndrome scores,pulmonary function tests,and asthma control questionnaire(ACQ) scores,were compared before and after the intervention,along with safety indicators such as adverse events,blood routine,urinalysis,blood biochemistry,and 12-lead electrocardiogram.Results:The baseline TCM syndrome score was(11.49±3.37) points,and the change from baseline after treatment was(-6.50±3.68) points,with a statistically significant difference(P<0.000 1).Pulmonary function indicators,including forced expiratory volume in one second(FEV1),forced vital capacity(FVC),FEV1/FVC,maximum mid-expiratory flow(MMEF),and peak expiratory flow(PEF),were(1.69±0.75) L,(2.59±0.90) L,(77.15±16.33)%,(1.37±0.81) L/s,and(3.18±2.24) L/s,respectively,at baseline.After treatment,the changes from baseline were(0.30±0.38) L,(0.29±0.40) L,(6.51±12.16)%,(0.37±0.69) L/s,and(0.60±1.51) L/s,with statistically significant differences(P<0.000 1).The baseline ACQ score was(1.61±0.51) points,and the change from baseline after treatment was(-0.76±0.42) points,with a statistically significant difference(P<0.000 1).A total of 42 adverse events were reported in 55 occurrences,with an incidence rate of 2.10%.The severity of adverse events was classified as “Grade 1” in 35 cases(1.75%) and “Grade 2” in 8 cases(0.40%).Conclusion:Danlong Oral Liquid effectively relieves heat wheezing syndrome symptoms,improves pulmonary function,and enhances asthma control,with good safety.